Profile data is unavailable for this security.
About the company
Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.
- Revenue in USD (TTM)74.23m
- Net income in USD-90.28m
- Incorporated2014
- Employees1.14k
- LocationBurning Rock Biotech LtdNo. 5 Xingdao Ring Road North, International Bio IslandGUANGZHOU 510005ChinaCHN
- Phone+86 18 501641666
- Websitehttps://www.brbiotech.com/
| Holder | Shares | % Held |
|---|---|---|
| Kynam Capital Management LPas of 31 Dec 2023 | 8.69m | 10.56% |
| Massachusetts Financial Services Co.as of 31 Dec 2023 | 4.05m | 4.91% |
| MFS International (UK) Ltd.as of 31 Dec 2023 | 3.56m | 4.32% |
| FIL Investment Advisors (UK) Ltd.as of 31 Dec 2023 | 2.81m | 3.41% |
| Millennium Management LLCas of 31 Dec 2023 | 1.74m | 2.12% |
| Nikko Asset Management Americas, Inc.as of 31 Dec 2023 | 667.07k | 0.81% |
| MFS International Singapore Pte. Ltd.as of 29 Feb 2024 | 348.28k | 0.42% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 345.30k | 0.42% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 319.81k | 0.39% |
| BofA Securities, Inc.as of 31 Dec 2023 | 291.65k | 0.35% |
